BSE filing, NSE: FREDUN. Summary written from the filing by ALFA Finder's alert engine.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,471.70
- Market cap
- ₹2,109 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 48.1×Sector 46.1×
- Promoter holding
- 43.62%-0.95% QoQ
- FII holding
- 0.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Convertible Warrants
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors on conversion of 14,667 warrants. The conversion follows the 1:2 bonus issue, which adjusted warrant entitlements.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026. The disclosure provides the equity holding structure for shareholders.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals filed a compliance certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. It confirms the processing of dematerialized shares for the quarter.
Fredun Pharmaceuticals Business Update
Fredun Pharma announces strategic pet-care acquisitions, capacity expansion, and a 100% branded portfolio target by 2029. H1 FY27 business update outlines multi-pillar growth transformation.
- manufacturing infrastructure (Palghar plant)
- 90000 sq. ft.
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals allotted 1,82,400 equity shares upon the conversion of 60,800 warrants. The company received total consideration of ₹7.60 Crore for this warrant conversion.
- Value
- ₹7.60 Cr
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals has allotted 1,82,400 equity shares following the conversion of 60,800 warrants into equity shares, completing the preferential issue conversion process.
Other results update announcements
All →Vaibhav Global Results Update
Vaibhav Global reported H1 & Q2 FY27 results via press release, with Q2 revenue up 7.0% to ₹938.4 crore and EBITDA of ₹76.2 crore. The release covers platform migration effects and segment performance.
InfoBeans Technologies Results Update
InfoBeans Technologies reported Q2 and H1 FY27 results, with H1 revenue up 30% to ₹322.6 crore and PAT up 22% to ₹47.9 crore. Management highlighted growth momentum, new clients and EBITDA gains.
OnEMI Technology Solutions Results Update
Kissht reported Q2FY27 PAT of ₹125 Crore, doubling year-on-year, with AUM up 68% to ₹9,317 Crore. Press release accompanies unaudited Q2 and H1 FY27 results.
GMR Airports Results Update
GMR Airports reported Q2FY27 total income up 12% YoY to INR 4,188 Crs and PAT of INR 65 Crs. The filing is a press release accompanying the un-audited quarterly results.
MosChip Technologies Results Update
MosChip's Q2 FY27 press release showed revenue of ₹119.08 Crore and an EBITDA loss of ₹18.82 Crore. Cost escalations on a turnkey ASIC project drove weaker profit.
Zensar Technologies Results Update
Zensar Technologies reported 4.1% sequential constant currency revenue growth to $166.2M for Q2FY27, with EBITDA margin at 15.8%. The release is a press release accompanying the quarterly results presentation.